ALFA Filings
Every announcement, straight from the exchange
Every Acutaas Chemicals earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
8 announcements
Acutaas reports high-growth Q2 fueled by pharma intermediates and CDMO scaling, despite commodity chemical phase-outs.
Q2 FY27 revenue ₹4,369 Mn (+42.7% YoY), EBITDA ₹1,760 Mn (+84.6%, 40.3% margin), PAT ₹1,231 Mn (+71.4%). FY27 revenue guidance raised; South Korea semiconductor-chemicals facility inaugurated.
Acutaas Chemicals delivered a robust Q1 FY27 with 59.1% revenue growth, fueled by strong CDMO and Advanced Pharmaceutical Intermediates (API) performance.
Acutaas Chemicals delivered strong Q1 FY27 results with 59% YoY revenue growth. Management is focused on scaling high-margin Pharma Intermediates and CDMO segments while maintaining operational efficiencies.
Acutaas Chemicals delivered record FY26 results with Revenue of ₹13,394 Mn and PAT of ₹3,564 Mn, driven by expansion in pharmaceutical and semiconductor segments.
Acutaas Chemicals delivered record FY26 performance with ₹1,339.4cr revenue and ₹356.4cr PAT, driven by strong CDMO business and portfolio reshuffling towards high-value pharmaceutical intermediates.
Acutaas Chemicals delivered strong performance in Q4 FY26, with revenue up 40% and PAT doubling, driven by the high-margin CDMO business and specialty chemicals recovery despite supply chain disruptions.
Acutaas Chemicals reported strong Q4FY26 results with 40.3% YoY revenue growth and record PAT margins of 31%. Strategy focuses on Battery Chemicals, Semiconductors, and Pharma CDMO.